

FR 1,515,046

---

Job No.: 1505-94834

Ref.: FR 1515046

Translated from French by the Ralph McElroy Translation Company  
910 West Avenue, Austin, Texas 78701 USA

REPUBLIC OF FRANCE  
MINISTRY OF INDUSTRY  
DEPARTMENT OF INDUSTRIAL PROPERTY  
FRENCH PATENT NO. 1,515,046

Int. Cl.: C 07 d // A 61 k  
Filing No.: 82,141  
Filing Date: November 2, 1966, 1:51 p.m., Paris  
Date Granted: January 22, 1968  
Date of Public Access to the Application: Bulletin officiel de la Propriete  
industrielle, No. 9, March 1, 1968

Patent application filed in the United States of America, on November 12, 1965, under  
No. 507,536 in the name of Mr. David Huntington Gould


PROCESS FOR IMPROVING ORAL HYGIENE AND DENTIFRICE COMPOSITION FOR  
ITS IMPLEMENTATION

Applicant: Company known as:  
Colgate-Palmolive Company,  
residing in the United States of  
America  
Agent: Cabinet Lavoix

The present invention relates to a process making it possible to improve oral hygiene, and more particularly, to a process for inhibiting the formation of dental plaque. The invention also relates to effective compositions for improving oral hygiene and inhibiting the formation of dental plaque, compositions which essentially include a nontoxic support and an effective quantity of halogenated benzimidazolyl guanidine and/or salts of the aforementioned guanidine with nontoxic acids.

The essential active constituent of a composition which can be used for oral hygiene care in order to inhibit the formation of plaque, whether the composition is in the form of lozenges, strips, liquid gurgling solution or mouthwash, toothpaste or toothpowder, etc., is

2-(dihalobenzimidazolyl) guanidine and or one of its salts with nontoxic acids. The free base, 2-(dihalobenzimidazolyl) guanidine, can be represented by the formula:



in which X is chlorine, bromine or iodine and



is a C<sub>6</sub> aromatic nucleus.

Although various imidazoles, benzimidazoles, guanidines and bisguanidines have proven in many cases to have antimicrobial power, no simple germicide is known which, when used in topical applications in the buccal cavity, inhibits the formation of plaque. The 2-(dihalobenzimidazolyl) guanidines have the particular capability of being absorbed by the protein materials and of being released by them in vitro. It is this particular combination of properties to which the advantage of the 2-(dihalobenzimidazolyl) guanidines, with regard to improvement of oral hygiene and in particular inhibition of the formation of plaque, can be attributed.

The active substance, that is, 2-(dihalobenzimidazolyl) guanidine, in which the halogen is bromine, iodine or chlorine, and in which the benzene nucleus is substituted by identical or different halogens in position 5,6- or 4,5- or 4,6- or 4,7-, is presented in the form of lozenges or chewing strips, gargling solutions or mouthwashes, toothpaste or toothpowder, in which the active substance is in solution or in suspension, with it possible for said active substance to be associated with other active agents such as Na<sub>2</sub>FPO<sub>3</sub>, for example, as well as antibiotics, such as tylosine and desmycosine, in order to obtain a better effect.

The 2-(dihalobenzimidazolyl) guanidines are effective both in the form of free bases and in the form of salts formed with nontoxic acids. Currently, among the 2-(dihalobenzimidazolyl) guanidines, it is 2-(5,6-dichlorobenzimidazolyl) guanidine which is preferred. As an example of the power of the 2-(dihalobenzimidazolyl) guanidines, the effectiveness of 2-(5,6-dichlorobenzimidazolyl) guanidine will be mentioned, which, by daily application of solutions or suspensions of the free base, hydrochloride and hemimalonate, has been revealed to improve oral hygiene and in particular, to inhibit formation of plaque.

In a general manner, oral hygiene is improved by putting the buccal cavity in contact with a 2-(dihalobenzimidazolyl) guanidine, at an effective concentration of at least approximately 0.01% in a nontoxic vehicle. Thus, for example, a chewing strip essentially contains

approximately 0.1-2% or approximately 5-100 mg per strip of 2-(dihalobenzimidazolyl) guanidine [2-(5,6-dichlorobenzimidazolyl) guanidine being currently preferred], approximately 30-70% of a compatible abrasive (such as talc, chalk, alumina, insoluble sodium metaphosphate, insoluble dicalcium phosphate), approximately 30-50% of nontoxic moistener (such as mannitol, sorbitol, for example), approximately 0.5-3% of a substance putting the detritus in suspension (such as carboxymethylcellulose, Irish moss), approximately 1-3% of a nontoxic detergent (in particular a sarcosinate such as sodium N-lauroyl sarcosinate), approximately 5% of a binder such as polyethylene glycol (with a molecular weight of approximately 6000), approximately 1-2% of a lubricant for a matrix (such as magnesium stearate), as well as flavoring agents, coloring agents and sweeteners, to make 100%.

A solution for rinsing the mouth includes:

- a. Approximately 0.01-0.5% 2-(dihalobenzimidazolyl) guanidine;
- b. Approximately 0.5-1% of a nonionic nontoxic detergent, such as a product of condensation of polyoxyethylenated sorbitan monostearate containing approximately 60 mol ethylene oxide, [or] of a cationic detergent, such as a quaternary ammonium salt (for example, diisobutylphenoxyethoxyethyltrimethylbenzylammonium chloride);
- c. Sweetening, flavoring and coloring agents and aqueous alcohol to make 100%.

A dental cream essentially containing approximately 0.1-2% 2-(dihalobenzimidazolyl) guanidine, approximately 30-60% of an abrasive (such as talc, chalk, alumina, insoluble sodium metaphosphate, anhydrous dicalcium phosphate), approximately 20-40% of a nontoxic moistener (such as sorbitol, mannitol, glycerol), approximately 1-3% of a nonionic, cationic or anionic detergent (preferably sodium N-lauroyl sarcosinate), and water to make 100%. Furthermore, it is possible to add a compound containing fluorine, such as  $\text{Na}_2\text{FPO}_3$ , NaF, so as to contribute 0.1% fluorine, an opacifier (such as titanium dioxide) in an effective quantity of approximately 0.4%, approximately 1-2% of a substance for putting the debris in suspension (for example, gum tragacanth, carboxymethylcellulose), as well as sweetening, flavoring and coloring agents.

Here is an example of a preferred composition for a chewing tablet:

① ingrédient	② Pourcentage en poids
2(5,6-dichlorobenzimidazolyl)-guanidine ..	1,00
Metaphosphate de sodium insoluble .....	31,69
Talc .....	0,50
Phosphate dicalcique (anhydre) .....	4,03
Mannitol .....	47,30
Acides .....	3,00
Carboxyméthylcellulose (7 MF) .....	1,25
N-lauroyl sarcosinate de sodium .....	2,25
Polyéthylène glycol (P.M. 6 000 environ) .....	5,00
Saccharine .....	0,25
Stéarate de magnésium .....	1,25
Arôme, colorant .....	2,48
	100,00

- Key: 1 Ingredient  
 2 Weight percentage  
 3 2-(5,6-Dichlorobenzimidazolyl) guanidine  
 Insoluble sodium metaphosphate  
 Talc  
 Dicalcium phosphate (anhydrous)  
 Mannitol  
 Starch  
 Carboxymethylcellulose (7 MP)  
 Sodium N-lauroyl sarcosinate  
 Polyethylene glycol (molecular weight approximately 6000)  
 Saccharin  
 Magnesium stearate  
 Flavor, coloring agent

Here is an example of a currently preferred composition for a mouth rinse:

1	Ingédient	2
	Isethionate de 2-(5,6-dichlorobenzimidazo- lyl)-guanidine .....	0,25
	Chlorure de diisobutylphénoxyéthoxyéthyl- diméthylbenzyl ammonium .....	0,075
3	Produit de condensation de monostéarate de sorbitan polyoxyéthylène contenant environ 60 moles d'oxyde d'éthylène	0,60
	Saccharine .....	0,025
	Alcool éthylique .....	14,70
	Eau, arôme et colorant .....	Le rest
		100,00

- Key: 1 Ingredient  
 2 Weight percentage  
 3 2-(5,6-Dichlorobenzimidazolyl) guanidine isethionate  
 Diisobutylphenoxyethoxyethyl dimethylbenzyl ammonium chloride  
 Product of condensation of polyoxyethylenated sorbitan monostearate containing  
 approximately 60 mol ethylene oxide  
 Saccharin  
 Ethyl alcohol  
 Water, flavor and coloring agent  
 4 The remainder

Here is an example of a currently preferred composition of a tooth cream:

1	Ingredient	2	Pourcentage en poids
3	Chlorhydrate de 2-(5,6-dichlorobenzimidazole)-		
	zyl-guanidine .....		0,50
	Benzoate de sodium .....		0,15
	Saccharine .....		0,20
	N-lauroyl sarcosinate de sodium .....		2,00
	Metaphosphate de sodium insoluble .....		40,60
	Phosphate dibasique .....		4,24
	Dioxyde de titane .....		0,40
	Na <sub>2</sub> FPO <sub>3</sub> .....		0,76
	Gomme adragante .....		1,40
	Glycérine (99,3 %) .....		27,10
	Eau, colorant, arôme .....		Le reste
			100,00

- Key: 1 Ingredient  
 2 Weight percentage  
 3 2-(5,6-Dichlorobenzimidazolyl) guanidine hydrochloride  
 Sodium benzoate  
 Saccharin  
 Sodium N-lauroyl sarcosinate  
 Insoluble sodium metaphosphate  
 Dicalcium phosphate  
 Titanium dioxide  
 Na<sub>2</sub>FPO<sub>3</sub>  
 Gum tragacanth  
 Glycerol (99.3%)  
 Water, coloring agent, flavor  
 4 The remainder

According to the preceding, it is quite obvious for the specialists that the 2-(dihalobenzimidazolyl) guanidines can be used in the form of free bases or of salts of nontoxic acids, in the form of solutions or suspensions in nontoxic solvents, nontoxic vehicles or nontoxic media. Since the preparation of the 2-(dihalobenzimidazolyl) guanidines is not the object of the present invention, and since their preparation, for example, from halogenated ortho-phenylenediamine and dicyanodiamide, is well known, it will not be described.

Of course, the invention is not limited to the embodiments described, which were only given as examples.

## Summary

The invention mainly relates to:

I. A process for improving oral hygiene and inhibiting the formation of dental plaque, said process being remarkable particularly by the following characteristics, considered separately or in combinations:

1. The buccal cavity is put in contact intermittently with a plaque inhibitor which is 2-(dihalobenzimidazolyl) guanidine or one of its salts with a nontoxic acid;

2. The inhibitor is 2-(5,6-dichlorobenzimidazolyl) guanidine and its salts with nontoxic acids, in a concentration of at least 0.01% in a nontoxic vehicle;

3. The inhibitor is presented in the form of a chewing strip containing approximately 0.1-2% 2-(dichlorobenzimidazolyl) guanidine and its salts of nontoxic acids, approximately 30-70% of a compatible abrasive, approximately 30-50% of nontoxic moistener, approximately 0.5-3% of a substance putting the detritus in suspension, approximately 1-3% of a nontoxic detergent, approximately 5% of a binder, approximately 1-2% of a lubricant for a matrix, as well as flavoring agents, coloring agents and sweeteners, to make 100%;

4. The inhibitor is presented in the form of a mouth rinse containing approximately 0.01-5% 2-(dihalobenzimidazolyl) guanidine chosen from 2-(5,6-dichlorobenzimidazolyl) guanidine and its salts of nontoxic acids, approximately 0.5-1% of a nontoxic detergent, a sweetener, aqueous ethyl alcohol, flavoring agents and coloring agents, to make 100%;

5. The plaque inhibitor is a dental cream containing approximately 0.1-2% 2-(dihalobenzimidazolyl) guanidine chosen from 2-(5,6-dichlorobenzimidazolyl) guanidine and its salts of nontoxic acids, 30-60% of an abrasive, approximately 20-40% of a nontoxic moistening agent, approximately 1-3% of a compatible nontoxic detergent, and water, to make 100%;

6. The inhibitor is presented in the form of a chewing strip which contains:  
(See 1<sup>st</sup> table, opposite column.)

7. The inhibitor is presented in the form of a mouth rinse which contains:  
(See 2<sup>nd</sup> table, opposite column.)

①	ingrédient	②	Pourcentage en poids
	2-(5,6-dichlorobenzimidazolyl)-guanidine ..		1.00
	Métaphosphate de sodium insoluble .....		31.69
	Talc .....		0.50
	Phosphate dicalcique (anhydre) .....		4.03
	Mannitol .....		47.80
	Amidon .....		3.00
	Carboxyméthylcellulose (7 H.P.) .....		1.25
	N-lauroyl sarcosinate de sodium .....		2.25
	Polyéthylène glycol (P.M. 6 000 environ) .....		5.00
	Saccharine .....		0.25
	Stéarate de magnésium .....		1.25
	Arôme, colorant .....		2.48
			100.00

Key: 1 Ingredient  
2 Weight percentage  
3 2-(5,6-Dichlorobenzimidazolyl) guanidine  
Insoluble sodium metaphosphate  
Talc  
Dicalcium phosphate (anhydrous)  
Mannitol  
Starch

Carboxymethylcellulose (7 MP)  
 Sodium N-lauroyl sarcosinate  
 Polyethylene glycol (molecular weight approximately 6000)  
 Saccharin  
 Magnesium stearate  
 Flavor, coloring agent

1	Ingédient	2	Pourcentage en poids
3	Iséthionate de 2-(5,6-dichlorobenzimidazole-lyl)-guanidine .....		0,35
	Chlorure de diisobutylphénoxyéthoxy-éthyl-diméthyl-benzyl ammonium .....		0,075
	Produit de condensation de monostéarate de sorbitan polyoxyéthylé contenant environ 60 moles d'oxyde d'éthylène .....		0,60
	Saccharine .....		0,035
	Alcool éthylique .....		14,78
	Eau, arôme et colorant .....		Le reste
			100,00

- Key: 1 Ingredient  
 2 Weight percentage  
 3 2-(5,6-Dichlorobenzimidazolyl) guanidine isethionate  
 Diisobutylphenoxyethoxyethyl dimethylbenzyl ammonium chloride  
 Product of condensation of polyoxyethylenated sorbitan monostearate containing approximately 60 mol ethylene oxide  
 Saccharin  
 Ethyl alcohol  
 Water, flavor and coloring agent  
 4 The remainder

8. The inhibitor is presented in the form of a dental cream which contains:

1	Ingédient	2	Pourcentage en poids
3	Chlorhydrate de 2-(5,6-dichlorobenzimidazole-lyl)-guanidine .....		0,50
	Benzoate de sodium .....		0,15
	Saccharine .....		0,20
	N-lauroyl sarcosinate de sodium .....		2,00
	Métophosphate de sodium insoluble .....		40,60
	Phosphate dicalcique .....		4,24
	Dioxyde de titane .....		0,10
	Na <sub>2</sub> PFO <sub>4</sub> .....		0,76
	Gomme adragante .....		1,40
	Glycérine (99,3 %) .....		27,10
	Eau, colorant, arôme .....		Le reste
			100,00

- Key: 1 Ingredient  
 2 Weight percentage  
 3 2-(5,6-Dichlorobenzimidazolyl) guanidine hydrochloride  
 Sodium benzoate  
 Saccharin  
 Sodium N-lauroyl sarcosinate



Insoluble sodium metaphosphate  
Dicalcium phosphate  
Titanium dioxide  
 $\text{Na}_2\text{FPO}_3$   
Gum tragacanth  
Glycerol (99.3%)  
Water, coloring agent, flavor  
4 The remainder

II. As a new industrial product, a composition for implementation of the process of the invention which is remarkable in that it essentially consists of approximately 0.01-2% of a 2-(dihalobenzimidazolyl) guanidine chosen from 2-(5,6-dihalobenzimidazolyl) guanidines, 2-(4,5-dihalobenzimidazolyl) guanidines, 2-(4,6-dihalobenzimidazolyl) guanidines, 2-(4,7-dihalobenzimidazolyl) guanidines and the salts of these guanidines and nontoxic acids, as well as a nontoxic vehicle.